Hood River Capital Management’s MoonLake Immunotherapeutics MLTX Stock Holding History

Hood River Capital Management’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-675,445	Closed	-$31.9M	–	167
2025 Q2	$31.9M	Buy	675,445 +12,462	+2%	+$508K	0.45%	80
2025 Q1	$25.9M	Buy	662,983 +13,393	+2%	+$577K	0.44%	85
2024 Q4	$35.2M	Buy	649,590 +2,928	+0.5%	+$150K	0.52%	77
2024 Q3	$32.6M	Buy	+646,662	New	+$30.3M	0.53%	71

Other funds holding MLTX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Hood River Capital Management's MLTX Position: Q3 2025 in Review

Hood River Capital Management sold out of MoonLake Immunotherapeutics (MLTX) in Q3 2025, closing a stake of 675,445 shares — an estimated $31.9M sold.

Hood River Capital Management first reported a position in MLTX in Q3 2024 and held it in 4 quarters. The position peaked at $35.2M in Q4 2024. 134 funds tracked by Wall St. Rank hold MLTX as of Q3 2025.

Hood River Capital Management reported no remaining MoonLake Immunotherapeutics position as of Q3 2025 after selling out during the quarter.
Hood River Capital Management sold 675,445 MoonLake Immunotherapeutics shares in Q3 2025, an estimated $31.9M.
Hood River Capital Management first reported a position in MoonLake Immunotherapeutics in Q3 2024 and held it in 4 quarters.
Hood River Capital Management's MoonLake Immunotherapeutics position peaked at $35.2M in Q4 2024.
134 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q3 2025.

Based on Hood River Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.